Floriano-Sánchez E, Cárdenas-Rodríguez N, Castro-Marín M, Flores-Terraza J, Torres-Salazar J

Language: Spanish
References: 17
Page: 84-91
PDF size: 1315.12 Kb.

ABSTRACT

Background: Recent reports have placed prostate cancer (CaP) as the third most common cancer worldwide and in Mexico it is the principal cause of death from cancer in men with more than 70% of cases presenting in advanced stages. Several genetic markers are being studied in CaP.Relatively few studies have been reported in the medical literature on the manganese superoxide dismutase (Mn-SOD) gene. The present study evaluated whether there was any alteration in Mn-SOD expression in CaP and benign prostatic hyperplasia (BPH).
Materials and methods: Forty BPH samples and 20 CaP samples were obtained and conditions were standardized to amplify the Mn-SOD gene. Amplification conditions were carried over to real time RT-PCR amplification protocol in “Rotor-Gene 3000” equipment and the number of absolute copies was determined for each sample.
Results: There was 3.15 times more Mn-SOD gene overexpression in the CaP group than in the BPH group. Mean absolute copy expression for BPH was 242.8 and for CaP was 765.7.
Conclusions: Mn-SOD gene expression in CaP had a greater statistical significance than in BPH, suggesting that this gene could be used as a tumor marker in biopsies of patients suspected of presenting with CaP.

REFERENCES

1. Hall SE, Holman CD, Wisniewski ZS. Prostate cancer: socio-economic, geographical and private-health insurance effects on care and survival. BJU Int 2005;95(1):51-58.

2. Ahmed MM, Lee CT, Oesterling JE. Current trend in the epidemiology of prostatic disease: benign hyperplasia and adenocarcinoma. Boca Raton, Florid. CRC Press, 1997.

3. Instituto Nacional de Cancerología, Manual de Oncología, Editorial McGrawHill, 2003.

4. Guess HA. Benign prostatic Hyperplasia: antecedents and natural history. Epidemiol Rev 1992;14:131-153.

5. Thorpe A, Neal D. Benign Prostatic Hyperplasia. Lancet 2003;361(9366):1359-1367.

6. Sarmina Y, Resnick MI. Obstructive uropathy in patients with benign prostatic hyperplasia. J Urol 1989;141(4):866-869.

7. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1990;17(3):495-507.

8. De Marzo AM, Nelson WG, Meeker AK. Stem cell features of benign and malignant prostate aepithelial cells. J Urol 1998;160(6 Pt 2): 2381-2392.

9. Hennekens CH. Antioxidant vitamins and cancer. Am J Med 1994;97(3A):2S-4S; discussion 22S-28S.

10. Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006;5:14.

11. Terry DO. Oxidative damage and cancer. AJP 2002;160:403-408.

12. Kahlos K, Anttila S, Asikainen T. Manganese superoxide dismutase in healthy human pleural mesothelium and in malignant pleural mesothelioma. Am J Respir Cell Mol Biol 1998;18(4):570–580.

13. Church SL, Grant JW, Ridnour LA. Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc Natl Acad Sci U S A;90(7):3113-3117.

14. Izutani R, Asano S, Imano M. Expression of manganese superoxide dismutase in esophageal and gastric cancers. J Gastroenterol 1998;33(6):816-822

15. Toshiyuki N, Keiichiro S, Junichi F. High expression of manganese superoxide dismutase in 7,12 dimethylbenz[a]anthracene-induced ovarian cancer and increased serum levels in the tumor-bearing rats. Carcinogenesis 1992;13:1941-1943.

16. Bostwick DG, Alexander EE, Singh R. Antioxidant Enzyme Expression and Reactive Oxygen Species Damage in Prostatic Intraepithelial Neoplasia and Cancer. Cancer 2000;89(1):123-134.

17. Hu Y, Rosen DG, Zhou Y. Mitochondrial manganese-superoxide dismutase expression in ovarian cancer role in cell proliferation and response to oxidative stress. J Biol Chem 2005;280(47):39485-39492